<DOC>
	<DOCNO>NCT00507637</DOCNO>
	<brief_summary>The objective Phase II study show pre-treated patient BEB need shorten injection interval achieve improve stable quality life level receive repeat NT 201 injection short injection interval . In addition , tolerability repeat shorten NT 201 administration patient BEB include development neutralize antibody investigate .</brief_summary>
	<brief_title>Blepharospasm Short Interval</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>A clinical diagnosis bilateral BEB characterize spontaneous , spasmodic , intermittent persistent involuntary contraction orbicular oculi muscle Medical need treatment shorten injection interval ( &lt; 12 week ) confirm patient investigator Blepharospasm Disability Index ( BSDI ) baseline visit injection &gt; / = 1,6 Atypical variant blepharospasm cause inhibition levator palpebrae muscle ( apraxia eyelid ) Generalized disorder muscle activity ( e.g . myasthenia gravis , LambertEaton syndrome ) , well amyotrophic lateral sclerosis significant neuromuscular disease might interfere trial The previous three injection Botulinum toxin Type A 50 Units [ U ] per eye per injection session Treatment Botulinum toxins indication BEB within 4 month prior baseline trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>